| scholarly article | Q13442814 |
| P50 | author | Mitchell Machtay | Q63151307 |
| Ritsuko Komaki | Q64585410 | ||
| Corey J Langer | Q119520375 | ||
| P2093 | author name string | Seth A Rosenthal | |
| Walter J Curran | |||
| Benjamin Movsas | |||
| Rebecca Paulus | |||
| James D Cox | |||
| William Sause | |||
| Stephen Hauser | |||
| Elizabeth Gore | |||
| Todd Wasserman | |||
| Jin S Lee | |||
| P2860 | cites work | Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. | Q33344687 |
| Sample size requirements for comparing time-to-failure among k treatment groups | Q41626506 | ||
| Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients | Q44808451 | ||
| Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study | Q45056439 | ||
| A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer | Q45232525 | ||
| Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 S | Q46641106 | ||
| Designs for group sequential tests. | Q52684721 | ||
| The randomization and stratification of patients to clinical trials | Q52895239 | ||
| Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol | Q61889869 | ||
| Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer | Q67485777 | ||
| Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06 | Q71121067 | ||
| Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study | Q71121071 | ||
| Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer | Q72134633 | ||
| Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15 | Q72146165 | ||
| Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the radiation therapy oncology group | Q72939403 | ||
| Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer | Q73181790 | ||
| Split-course radiotherapy with or without concurrent or sequential chemotherapy in non-small cell lung cancer | Q73974772 | ||
| Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973) | Q79329348 | ||
| Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma | Q81312777 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| chemoradiotherapy | Q5090613 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 1452-1460 | |
| P577 | publication date | 2011-09-08 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. | |
| P478 | volume | 103 |
| Q27002509 | 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer |
| Q37417099 | 4DCT and CBCT based PTV margin in Stereotactic Body Radiotherapy(SBRT) of non-small cell lung tumor adhered to chest wall or diaphragm |
| Q27014978 | 50 Years of progress in the systemic therapy of non-small cell lung cancer |
| Q33786722 | A Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung Cancer |
| Q37126741 | A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer |
| Q35836792 | A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533 |
| Q28079625 | A critical review of recent developments in radiotherapy for non-small cell lung cancer |
| Q64071662 | A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer |
| Q44794265 | A decade of community-based outcomes of patients treated with curative radiotherapy with or without chemotherapy for non-small cell lung cancer |
| Q33946208 | A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer |
| Q92067247 | A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer |
| Q64286235 | A novel approach for salvage treatment of non-small-cell lung cancer: percutaneous CT fluoroscopy-guided permanent seed brachytherapy for salvage treatment of lung cancer: long-term results of a case series |
| Q35848165 | A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response |
| Q35058595 | A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321 |
| Q37716645 | A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer |
| Q35986369 | A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer |
| Q92424817 | A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer |
| Q45923193 | A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. |
| Q59799824 | A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer |
| Q40155605 | A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer |
| Q53629230 | A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC). |
| Q38233740 | A review of the management of elderly patients with non-small-cell lung cancer. |
| Q45820484 | A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer |
| Q35914347 | Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer |
| Q37601098 | Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: evaluation of response, survival, toxicity and quality of life from a Phase II randomized study |
| Q41670890 | Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer |
| Q40541273 | Addition of Surgery After Radiation Significantly Improves Survival in Stage IIIB Non-small Cell Lung Cancer: A Population-Based Analysis |
| Q97538076 | Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery |
| Q57172945 | Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy |
| Q26766530 | Advances in dosimetry and biological predictors of radiation-induced esophagitis |
| Q64325572 | Advances in proton therapy in lung cancer |
| Q58804844 | Advances in radiation therapy for thoracic malignancies |
| Q47383621 | Akt1 Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in a Rad51-Dependent Manner |
| Q94491922 | Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic |
| Q58754674 | Amifostine- and chemoradiotherapy-related esophagitis in small cell lung cancer: a single institutional series and literature update |
| Q52863753 | An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer. |
| Q64988781 | An Economic Analysis of Radiation Therapy Oncology Group 94-10: Cost-Efficacy of Concurrent vs. Sequential Chemoradiotherapy. |
| Q38109469 | Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer |
| Q104135107 | Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited) |
| Q55036513 | Breaking the dose ceiling: proton therapy for locally advanced non-small cell lung cancer. |
| Q47769984 | Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer |
| Q36101108 | C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression |
| Q34466023 | CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma |
| Q47171167 | Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters |
| Q50781644 | Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010. |
| Q36989648 | Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer |
| Q92169285 | Chemotherapy for Lung Cancer in the Era of Personalized Medicine |
| Q38849044 | Chemotherapy in non-small cell lung cancer: opportunities for advancement |
| Q38838014 | Chemotherapy remains an essential element of personalized care for persons with lung cancers |
| Q30871677 | Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data |
| Q91844914 | Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer |
| Q64073728 | Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer |
| Q57071360 | Clinical, dosimetric, and position factors for radiation-induced acute esophagitis in intensity-modulated (chemo)radiotherapy for locally advanced non-small-cell lung cancer |
| Q64946952 | Combined Chemoradiotherapy-induced Weight Loss Decreases Survival in Locally Advanced Non-small Cell Lung Cancer Patients. |
| Q36993644 | Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations |
| Q64105066 | Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis |
| Q99578904 | Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study |
| Q53216825 | Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. |
| Q38696794 | Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience |
| Q41431618 | Comparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy |
| Q33412557 | Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. |
| Q37605623 | Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy |
| Q90452656 | Concurrent chemo-radiotherapy for unresectable non-small cell lung cancer invading adjacent great vessels on radiologic findings: is it safe? |
| Q88477815 | Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group |
| Q40339097 | Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study |
| Q36395262 | Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer |
| Q35167387 | Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience |
| Q34672375 | Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer |
| Q33420193 | Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer |
| Q26851579 | Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature |
| Q41081663 | Cons: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with inoperable large volume stage III non-small cell lung cancer |
| Q35810871 | Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy--retrospective analysis of 203 cases |
| Q38176433 | Controversies in the management of stage III non-small-cell lung cancer |
| Q38869464 | Crizotinib-loaded polymeric nanoparticles in lung cancer chemotherapy |
| Q36710620 | DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume |
| Q37714576 | DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints. |
| Q36855596 | DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer |
| Q55010544 | Decision analytic modeling for the economic analysis of proton radiotherapy for non-small cell lung cancer. |
| Q35911195 | Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma |
| Q36186918 | Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer |
| Q38902680 | Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery |
| Q36128358 | Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer |
| Q27027626 | Definitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionation |
| Q42363750 | Definitive radiotherapy with concurrent oncothermia for stage IIIB non-small-cell lung cancer: A case report |
| Q59127541 | Delineation of lung cancer with FDG PET/CT during radiation therapy |
| Q41443083 | Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value |
| Q37528298 | Did dose escalated radiotherapy in stage III non-small cell lung cancer improve overall survival? |
| Q37599284 | Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation |
| Q89757806 | Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two p |
| Q41110142 | Dose escalation for locally advanced lung cancer using adaptive radiation therapy with simultaneous integrated volume-adapted boost |
| Q38549486 | Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line? |
| Q61582903 | Dose escalation in lung cancer: have we gone full circle? |
| Q37037949 | Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer |
| Q36958517 | Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy |
| Q36279626 | Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer |
| Q41039681 | Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer |
| Q41257238 | Dosimetric comparison of carbon ion and X-ray radiotherapy for Stage IIIA non-small cell lung cancer |
| Q47972027 | Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study. |
| Q55079845 | Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer. |
| Q55304879 | Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. |
| Q37180302 | EGFR inhibition in non-small cell lung cancer: current evidence and future directions |
| Q96305368 | Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience |
| Q42342006 | Editorial on: multidisciplinary therapy of marginally operable stage IIIA non-small cell lung cancer |
| Q92082865 | Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial |
| Q45063752 | Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study |
| Q38376135 | Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial. |
| Q36482508 | Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy |
| Q36143838 | Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer |
| Q91606046 | Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial |
| Q57817705 | Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly |
| Q91655310 | Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non-small-cell lung cancer: A meta-analysis and systematic review |
| Q39393466 | Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy. |
| Q41475564 | Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy |
| Q38907439 | Enhanced antiproliferative and apoptosis effect of paclitaxel-loaded polymeric micelles against non-small cell lung cancers |
| Q57075013 | Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro |
| Q35768924 | Esophagus and Contralateral Lung-Sparing IMRT for Locally Advanced Lung Cancer in the Community Hospital Setting |
| Q47356300 | Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy. |
| Q36239986 | FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy |
| Q36239958 | FePt nanoparticles as a potential X-ray activated chemotherapy agent for HeLa cells |
| Q92643772 | FePt/GO Nanosheets Suppress Proliferation, Enhance Radiosensitization and Induce Autophagy of Human Non-Small Cell Lung Cancer Cells |
| Q89572724 | Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies |
| Q42668963 | Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation |
| Q104135104 | Foreword to 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms' |
| Q39041541 | From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage? |
| Q35190878 | Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trial |
| Q28086993 | Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR |
| Q36185983 | HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer |
| Q47189971 | Health care disparities among octogenarians and nonagenarians with stage III lung cancer |
| Q47129493 | Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer |
| Q37114850 | High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study |
| Q36543330 | Hope for progress after 40 years of futility? Novel approaches in the treatment of advanced stage III and IV non-small-cell-lung cancer: Stereotactic body radiation therapy, mediastinal lymphadenectomy, and novel systemic therapy |
| Q89017230 | How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience |
| Q37470072 | Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation |
| Q37670429 | Hyperfractionated and accelerated radiotherapy in non-small cell lung cancer |
| Q58112087 | Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)-Lung Working Group |
| Q90685332 | Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy |
| Q48505571 | INTEGRATED CARE PATHWAYS IN LUNG CANCER: A QUALITY IMPROVEMENT PROJECT. |
| Q57022957 | Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database |
| Q40102857 | Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy |
| Q41378041 | Image guided radiation therapy may result in improved local control in locally advanced lung cancer patients |
| Q56891772 | Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer |
| Q26738359 | Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment |
| Q33621874 | Immunological Aspect of Radiation-Induced Pneumonitis, Current Treatment Strategies, and Future Prospects |
| Q38230278 | Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines |
| Q55322253 | Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? |
| Q64998544 | Immunotherapy in inoperable stage III non-small cell lung cancer: a review. |
| Q38549598 | Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation? |
| Q64881434 | Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy. |
| Q39052564 | Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial |
| Q87898981 | Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy |
| Q39510875 | Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. |
| Q30985297 | Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data |
| Q37188521 | Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles |
| Q34564219 | Improving chemoradiotherapy with nanoparticle therapeutics |
| Q38406514 | Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status |
| Q55529918 | Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis. |
| Q34503889 | Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial |
| Q30791401 | Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base |
| Q34462689 | Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer |
| Q36439428 | Infrequent chemoradiation-induced acute esophagitis in the Asian population: A meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer |
| Q93103866 | Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analys |
| Q38771934 | Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. |
| Q38243178 | Integrating stereotactic body radiation therapy in stage II/III non-small cell lung cancer: is local control important? |
| Q38350598 | Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer. |
| Q36887292 | Intra- and Inter-Fractional Variation Prediction of Lung Tumors Using Fuzzy Deep Learning. |
| Q86068874 | Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer |
| Q36609568 | Is a Clinical Target Volume (CTV) Necessary in the Treatment of Lung Cancer in the Modern Era Combining 4-D Imaging and Image-guided Radiotherapy (IGRT)? |
| Q48546289 | Is a clinical target volume (CTV) necessary for locally advanced non-small cell lung cancer treated with intensity-modulated radiotherapy? -a dosimetric evaluation of three different treatment plans |
| Q89116529 | Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer? |
| Q37618701 | Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy? |
| Q44772308 | Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis |
| Q38558894 | Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration |
| Q90100983 | Locally Advanced, Unresectable Non-Small Cell Lung Cancer |
| Q34135928 | Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer |
| Q50862063 | Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. |
| Q39019487 | Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). |
| Q90669424 | Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy |
| Q30235908 | Lung cancer in Brazil: epidemiology and treatment challenges |
| Q34359347 | Lung cancer treatment disparities in China: a question in need of an answer |
| Q38940816 | Lung cancer: current therapies and new targeted treatments |
| Q36167697 | Lung cancer: treatment pathway in the radiotherapy department at the National Oncology Institute of Rabat |
| Q47098433 | Lung reirradiation with stereotactic body radiotherapy |
| Q91795860 | Machine learning highlights the deficiency of conventional dosimetric constraints for prevention of high-grade radiation esophagitis in non-small cell lung cancer treated with chemoradiation |
| Q36811458 | Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung). |
| Q36355802 | Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung cancer patients treated with concurrent radiotherapy and chemotherapy |
| Q37031569 | Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment |
| Q50071627 | MiR-186 inhibits proliferation, migration, and invasion of non-small cell lung cancer cells by downregulating Yin Yang 1. |
| Q37329410 | Modern radiotherapy using image guidance for unresectable non-small cell lung cancer can improve outcomes in patients treated with chemoradiation therapy |
| Q33583931 | Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision |
| Q85905334 | Multimodal treatment of non-small-cell lung cancer |
| Q38930358 | Multimodality Therapy for NSCLC. |
| Q36838995 | Nanomedicine in chemoradiation. |
| Q34763290 | National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer |
| Q47170209 | Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer |
| Q52338636 | Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. |
| Q35669846 | Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid). |
| Q26827571 | Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer |
| Q26775388 | Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies |
| Q87513859 | Older patients with inoperable non-small cell lung cancer: long-term survival after concurrent chemoradiotherapy |
| Q58804840 | Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer |
| Q51687784 | Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy. |
| Q38444980 | PET in the management of locally advanced and metastatic NSCLC. |
| Q99582968 | PET-Plan: potential for dose escalation by target volume reduction in locally advanced NSCLC |
| Q54974804 | Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study. |
| Q55073985 | Particle therapy in non-small cell lung cancer. |
| Q38682031 | Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer |
| Q36924273 | Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity? |
| Q37498889 | Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey |
| Q39720229 | Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma |
| Q89799444 | Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial |
| Q33428645 | Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001). |
| Q37516506 | Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer |
| Q33401530 | Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer |
| Q55284746 | Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer. |
| Q54685400 | Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401. |
| Q36946823 | Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer |
| Q37176293 | Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT. |
| Q36368864 | Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. |
| Q54985181 | Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy. |
| Q30868582 | Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base |
| Q64275489 | Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy |
| Q47142302 | Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer. |
| Q47342475 | Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels |
| Q42659931 | Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model |
| Q36061153 | Predictors for Severe Acute Esophagitis in Lung Cancer Patients Treated with chemoradiotherapy: a systematic review |
| Q90427294 | Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer |
| Q36786779 | Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer. |
| Q91814559 | Pretreatment SUVmax value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy |
| Q95723917 | Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients |
| Q49713310 | Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer |
| Q36824972 | Prognostic performance of inflammation-based prognostic indices in locally advanced non-small-lung cancer treated with endostar and concurrent chemoradiotherapy |
| Q36874790 | Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer |
| Q38669946 | Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study |
| Q38543109 | Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions |
| Q41546002 | Proton beam therapy in non-small cell lung cancer: state of the art. |
| Q50050183 | Proton therapy for non-small cell lung cancer: Current evidence and future directions |
| Q54968869 | Proton therapy for thoracic reirradiation of non-small cell lung cancer. |
| Q92119093 | Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer |
| Q64916385 | Radiation Pneumonitis: Old Problem, New Tricks. |
| Q30278410 | Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials |
| Q26823043 | Radiation dose effect in locally advanced non-small cell lung cancer |
| Q37007890 | Radiation therapy for early stage lung cancer |
| Q36196702 | Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones |
| Q26765355 | Radio(chemo)therapy in locally advanced nonsmall cell lung cancer |
| Q38918757 | Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460. |
| Q42363788 | Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"? |
| Q95406381 | Radiotherapy toxicity |
| Q38718558 | Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. |
| Q104135106 | Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer |
| Q55312880 | Re-irradiation in lung disease by SBRT: a retrospective, single institutional study. |
| Q41081446 | Rebuttal from Prof. Kong and Dr. Rabatic. |
| Q97518316 | Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group |
| Q41675808 | Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy |
| Q36534788 | Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer |
| Q58804832 | Reirradiation for locoregionally recurrent non-small cell lung cancer |
| Q37597937 | Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer |
| Q99241033 | Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada |
| Q59811008 | Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients |
| Q42290357 | Risk Factors for Nephrotoxicity Associated with Cisplatin. |
| Q33994465 | Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy |
| Q92016948 | Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer |
| Q38925887 | Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer |
| Q35200337 | Role of HGF/MET axis in resistance of lung cancer to contemporary management |
| Q37484854 | Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective |
| Q51825980 | Role of surgery in clinical N2 non-small-cell lung cancer: a pro and con debate; the 'con' viewpoint. |
| Q61447200 | S-1 plus cisplatin with concurrent radiotherapy for stage III non-small cell lung cancer: A meta-analysis (PRISMA) of randomized control trials |
| Q34954169 | Safety and Tolerability of SBRT after High-Dose External Beam Radiation to the Lung |
| Q43561521 | Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer |
| Q92072927 | Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients |
| Q41472312 | Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study |
| Q33782351 | Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study |
| Q40382618 | Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer |
| Q91630556 | Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort |
| Q35568485 | Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto |
| Q38390036 | State of the art of radiotherapy. |
| Q41034587 | Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study. |
| Q61804651 | Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer |
| Q35143867 | Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses |
| Q38226816 | Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond |
| Q47099923 | Survival and prognostic factors of non-small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy |
| Q88661976 | Synchronous Chemoradiation Nanovesicles by X-Ray Triggered Cascade of Drug Release |
| Q92281451 | Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution |
| Q41339882 | Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials |
| Q64071654 | Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy |
| Q35725518 | The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells |
| Q41455781 | The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer. |
| Q36823982 | The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. |
| Q49826396 | The biology and management of non-small cell lung cancer |
| Q36547835 | The clinical case for proton beam therapy. |
| Q104135105 | The current treatment landscape in the UK for stage III NSCLC |
| Q30239983 | The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis |
| Q36287297 | The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis |
| Q34720945 | The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy |
| Q33829279 | The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy |
| Q64118063 | The prognostic value of Tiam1 correlates with its roles in epithelial-mesenchymal transition progression and angiogenesis in lung adenocarcinoma |
| Q38663176 | The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients |
| Q38115503 | The role of consolidation treatment in locally advanced unresectable NSCLC. |
| Q37589335 | The use of dose-escalated radiation for locally advanced non-small cell lung cancer in the U.S., 2004-2013. |
| Q37642455 | Therapeutic management options for stage III non-small cell lung cancer |
| Q33428648 | Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer. |
| Q33401383 | Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). |
| Q36835347 | Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). |
| Q84202706 | Treating elderly patients with stage III NSCLC |
| Q47158407 | Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer |
| Q36051895 | Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies |
| Q64907648 | Trends and Patterns of Disparities in Burden of Lung Cancer in the United States, 1974-2015. |
| Q58727065 | Triggered radiosensitizer delivery using thermosensitive liposomes and hyperthermia improves efficacy of radiotherapy: An in vitro proof of concept study |
| Q53199885 | Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoo |
| Q90825996 | Use of high and very high dose radiotherapy after radical prostatectomy for prostate cancer in the United States |
| Q37722169 | Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients. |
| Q41544840 | Weight gain as a surrogate marker of longer survival in advanced non-small cell lung cancer patients |
| Q38711723 | What is changing in radiotherapy for the treatment of locally advanced nonsmall cell lung cancer patients? A review. |
| Q92326446 | Whole-tumor perfusion CT using texture analysis in unresectable stage IIIA/B non-small cell lung cancer treated with recombinant human endostatin |
| Q89862643 | [Advances and Challenges of Local Thermal Ablation in Non-small Cell Lung Cancer] |
| Q87423478 | [Concurrent radiochemotherapy for the treatment of solid tumors] |
| Q55455379 | [Lung Nodules Assessment--Analysis of Four Guidelines]. |
| Q86964709 | [Progression-free survival of patients with locally advanced NSCLC not improved by consolidation chemotherapy after concurrent chemoradiation] |
| Q55496722 | [Research Advances of Pan-negative Type of Non-small Cell Lung Cancer]. |
| Q64097879 | hMOF reduction enhances radiosensitivity through the homologous recombination pathway in non-small-cell lung cancer |
Search more.